
Active Biotech Q1 2025 - Important results with laquinimod

Redeye comments on Active Biotech's Q1 report 2025. In May, the company reported positive topline data in the biodistribution study of laquinimod, potentially setting it up for a deal. The first patients were recruited to the American and European studies of tasquinimod in myelofibrosis. Importantly, NeoTX has continued its study of naptumomab, which we consequently add back to our base case.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Active Biotech Q1 2025 - Important results with laquinimod